文献速递肿瘤 PET/CT核素与放射性配体治疗

评估局部区域治疗对肝细胞癌代谢肝功能的影响:18F-FDGal PET/CT研究

Evaluation of the effect of locoregional treatment on metabolic liver function in hepatocellular carcinoma using 18F-FDGal PET/CT.
PubMed 文献 · EJNMMI Res · 2025-07-16

本研究纳入29例肝细胞癌患者,分别接受切除(8例)、射频消融(8例)、经动脉化疗栓塞(9例)和选择性内照射治疗(4例),采用18F-FDGal PET/CT评估肿瘤对总代谢肝功能的贡献及治疗后代谢肝功能变化。结果显示>3cm的肝细胞癌对肝脏半乳糖代谢有显著贡献,治疗后代谢肝功能变化取决于肝硬化状态和治疗类型,功能肝体积变化不一定反映总代谢能力。

要点

  • >3cm的肝细胞癌对肝脏总代谢活性有显著贡献(p=0.0002)。
  • 无肝硬化患者治疗后平均代谢活性中位变化为5.1%,肝硬化患者为-6.0%(p=0.05)。
  • 切除术后8例中7例平均代谢肝功能升高或稳定,射频消融、经动脉化疗栓塞和选择性内照射治疗反应不一。

核心结论

  • >3cm的肝细胞癌对肝脏半乳糖代谢有显著贡献,提示这一结论可能也适用于其他用于测量代谢肝功能的底物。
  • 治疗后代谢能力的变化取决于肝硬化状态和治疗类型。
  • 功能肝体积的变化不一定反映总代谢能力。
  • 本研究强调了基于影像的代谢肝功能定量的价值。

研究设计与样本

  • 研究纳入29例肝细胞癌患者,接受切除(n=8)、射频消融(n=8)、经动脉化疗栓塞(n=9)和选择性内照射治疗(n=4)。
  • 采用18F-FDGal PET/CT测定大肝癌对总代谢肝功能的贡献及治疗后代谢肝功能变化。

主要发现

  • 在肝细胞癌>3cm的患者中,纳入代谢活跃肿瘤区域时肝脏总代谢活性显著高于排除肿瘤时(p=0.0002)。
  • 局部区域治疗后肝脏平均代谢活性中位百分比变化在无肝硬化患者为5.1%,在肝硬化患者为-6.0%(p=0.05)。
  • 肝硬化(总共n=15)在各治疗组间分布不均。
  • 治疗后切除组8例中7例平均代谢肝功能升高或稳定,而射频消融、经动脉化疗栓塞或选择性内照射治疗组反应不一。
  • 平均代谢肝功能变化与肝体积变化不相关。

局限性

  • 肝硬化(总共n=15)在各治疗组间分布不均。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The effect of different locoregional treatments for hepatocellular carcinoma (HCC) on metabolic liver function is largely unknown. This information is crucial, particularly for patients with cirrhosis. We applied [18F]-fluoro-2-deoxy-D-galactose (18F-FDGal) positron emission tomography (PET) to determine the contribution of large HCCs to total metabolic liver function and the changes in metabolic liver function post-treatment. RESULTS: We included 29 patients with HCC treated with resection (n = 8), radiofrequency ablation (RFA) (n = 8), transarterial chemoembolization (TACE) (n = 9), and selective internal radiation therapy (SIRT) (n = 4). In patients with HCCs > 3 cm, the liver’s total metabolic activity was significantly higher when including the metabolically active tumor areas compared to when the tumor was excluded (p = 0.0002). The median percent change in mean metabolic activity in the liver after locoregional treatment was 5.1% in patients without cirrhosis as compared to -6.0% in patients with cirrhosis (p = 0.05). The distribution of cirrhosis (n = 15 in total) among treatment groups was uneven. After treatment, seven of eight patients who underwent resection showed increased or stable mean metabolic liver function, while responses for those treated with RFA, TACE, or SIRT were mixed. Changes in mean metabolic liver function and liver volume did not correlate. CONCLUSIONS: HCCs > 3 cm contributed substantially to the liver’s galactose metabolism, suggesting that this would also apply to other substrates used for measuring metabolic liver function. Changes in metabolic capacity following treatment depend on cirrhosis status and type of treatment. Changes in functional liver volume do not necessarily reflect total metabolic capacity. The study underlines the power of imaging-based quantification of metabolic liver function.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Kristiansen MK, Bak-Fredslund KP, Kramer S, et al. Evaluation of the effect of locoregional treatment on metabolic liver function in hepatocellular carcinoma using 18F-FDGal PET/CT. EJNMMI Res. 2025. PMID: 40670837. doi:10.1186/s13550-025-01285-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。